The aim of the present study was to compare the effects of full-length rat kisspeptin (rKp-52) with C-terminal decapeptide (Kp-10) of rat or human kisspeptin on LH release in intact male rats. Plasma LH profiles were determined by frequent blood sampling at 6-min intervals for 3 h after central or peripheral injection of kisspeptins. Intracerebroventricular (icv) injection of rKp-52 (0.1 nmol) induced a gradual increase in the plasma LH level, which remained high for the rest of the sampling period. On the other hand, icv injection of rKp-10 did not increase the plasma LH level at the same dose (0.1 nmol). A 10-times higher dose (1 nmol) of rKp-10 and hKp-10 increased the plasma LH level, but the increase was lower than that of rKp-52 icv injection. Intravenous (iv) injection of kisspeptins also stimulated LH release at 10 or 100 nmol/kg. In rKp-52 (10 nmol/kg)-treated animals, the plasma LH level reached a peak within 30 min and remained high until 60 min postinjection. The rKp-10-and hKp-10-injected animals showed a more rapid decline in plasma LH level after the peak found at around 30 min after the injections at both middle (10 nmol/kg) and high (100 nmol/kg) doses. The present study indicates that full-length kisspeptin is more effective in stimulating LH release compared with Kp-10 in male rats. The difference in LH-releasing activity may be the result of a difference in degradation of the peptides, but it is still worth determining whether an active domain other than the Cterminal decapeptide is present in full-length kisspeptin.
(J. Reprod. Dev. 55: [378] [379] [380] [381] [382] 2009) isspeptin (also known as metastin) [1] , a hypothalamic C-terminal amidated peptide, plays a key role in regulating reproductive function in mammals [2] [3] [4] [5] [6] [7] [8] [9] [10] . Previously deduced amino acid sequences of rat kisspeptin show that the C-terminal amidated 10-amino-acid sequence (rat Kp-10, YNWNSFGLRY-NH2) is identical to other mammalian species examined except for primates that have phenylalanine at the C-terminal [1, 11] . Ohtaki et al. [1] showed that the C-terminal Kp-10 sequence is involved in in vitro receptor activation. The C-terminal decapeptide is more effective than full-length kisspeptin in hOT7T175 (nearly identical to KISS1R, kisspeptin receptor)-expressing cells, as shown by FLIPR assay. The C-terminal nonapeptide is less effective compared with full-length kisspeptin, indicating that the decapeptide is mostly involved in receptor interaction [1] .
Earlier in vivo studies have shown that both full-length kisspeptin and its C-terminal decapeptide stimulate gonadotropin release when injected peripherally or centrally in rats [12] [13] [14] [15] [16] , mice [17, 18] and monkeys [19] . The stimulatory action of kisspeptins on gonadotropin release appears to be mediated by gonadotropinreleasing hormone (GnRH) release, as GnRH antagonist prevents this response [13, 17] . The GnRH neuronal terminal in the median eminence, which has no blood-brain barrier [20] , is a candidate for the action site of kisspeptins controlling GnRH release. Kisspeptin stimulates in vitro GnRH release from tissue fragments of the mediobasal hypothalamus (MBH) [21] , and KISS1R might be located in the MBH, where few GnRH cell bodies are found.
It should be noted that gonadotropin-releasing activities might not necessarily be consistent between full-length kisspeptin and Kp-10. Navarro et al. [14] have first shown a long-lasting stimulatory effect of intracerebroventricular (icv) injection of mouse Kp-10 on luteinizing hormone (LH) release in a rat model. Thompson et al. [15] also reported a longer effect of icv injection of human Kp-10 (hKp-10) compared with intravenous (iv) injection of hKp-10 in male rats. Shahab et al. [19] showed only a transient increase in plasma LH levels in agonadal male rhesus monkeys when hKp-10 was injected centrally or peripherally. On the other hand, icv injection of human full-length kisspeptin (hKp-54) showed much more potent stimulation of LH release [16] compared with Kp-10induced LH release [14] in rats. Thompson et al. [22] also reported that full-length kisspeptin is more potent than C-terminal fragments when injected peripherally. Thus, it would be worthwhile to compare the in vivo LH-releasing activities of full-length kisspeptin and C-terminal fragments of the peptide.
The aim of the present study was to compare the effects of fulllength rat kisspeptin (rKp-52), rat Kp-10 (rKp-10) and hKp-10 on LH release in male rats with central or peripheral injection. To this end, plasma LH profiles were monitored in male rats by frequent blood sampling after icv or iv injection of kisspeptins.
Materials and Methods

Animals and blood sampling
Wistar-Imamichi strain male rats, weighing 250-350 g at 8-10 weeks of age, were maintained in a controlled environment (14 h light and 10 h darkness, lights on at 0500 h, 23 ± 2 C) with free access to food (CE-2, CLEA Japan, Tokyo, Japan) and water. The animals were handled daily for at least 1 week before blood sampling. Blood samples were collected every 6 min for 3 h from freely-moving conscious rats via a silicon cannula (i.d., 0.5 mm; o.d., 1.0 mm; Shin-Etsu Polymer, Tokyo, Japan) that was inserted into the right atrium through the jugular vein on the day before the blood sampling. An equivalent volume of rat red blood cells taken from donor rats and suspended in heparinized saline was replaced through the atrial cannula after each blood collection. Plasma was separated by centrifugation and stored at -20 C until LH assay. Surgeries were conducted under inhalational anesthesia using isoflurane and aseptic conditions. All the animal experiments were approved by the Committee on Animal Experiments of the Graduate School of Bioagricultural Sciences, Nagoya University.
Intracerebroventricular injection of kisspeptin or Kp-10
A stainless-steel guide cannula (22G, Plastics One, Roanoke, VA, USA) was inserted into the third cerebroventricle with its tip 0.8 mm caudal to the bregma, 7.5 mm below the surface of the skull and in the midline according to the coordinates of the rat brain atlas [23] . Rat full-length kisspeptin (0.1 nmol/2 μl, n=5), rKp-10 (0.1 or 1 nmol/2 μl, n= 3-5), hKp-10 (0.1 or 1 nmol/2 μl, n=5) or vehicle (ultra-pure water, 2 μl, n=3) was injected into the third ventricle through an inner cannula (28G, Plastics One), which was inserted into the guide cannula, using a microsyringe pump (EICOM, Kyoto, Japan) at a flow rate of 1 μl/min immediately after the first sampling at 1300 h. The amino acid sequences of rat and human kisspeptins are shown in Fig. 1 [1, 11] . All the peptides used in the present study were synthesized by the Peptide Institute Inc. The correct structures of the synthetic peptides were confirmed by mass and amino acid analyses. The purity of the peptides was more than 96%.
At the end of blood sampling, the animals were anesthetized and infused with a 2-μl solution of 3% brilliant blue at the same flow rate as the experiment. The brain was removed, and cannula placement was verified by visual inspection. All animals used were confirmed to have correct cannula placement.
Intravenous injection of kisspeptin or Kp-10
Rat kisspeptin (1-52)-amide (1 or 10 nmol/kg body weight, n= 5), rKp-10 (1, 10 or 100 nmol/kg, n=4-5), hKp-10 (10 or 100 nmol/ kg, n=5) or saline as a vehicle (2 ml/kg) was intravenously injected through a silicon cannula immediately after the first sampling at 1300 h (8 h after lights on).
LH assay
Plasma LH concentrations were determined by a double-antibody radioimmunoassay (RIA) with a rat LH RIA kit provided by the National Hormone and Peptide Program (Torrance, CA, USA) and were expressed in terms of the NIDDK rLH RP-3. The least detectable level of the LH assay was 7.8 pg/tube, and the intra-and inter-assay coefficients of variation were 5.6 and 9.4% at 45 pg/ tube, respectively.
Data analysis and statistics
The area under the curve (AUC) of each plasma LH profile was calculated separately for each hour to analyze the time course of LH secretion after kisspeptin administration. Averages of the AUC values at each time point were then calculated for each group. Statistical differences in AUC values between groups were determined by one-way ANOVA followed by Fisher's PLSD.
Results
Effect of icv or iv injection of kisspeptins on plasma LH profiles in male rats
Plasma LH concentration showed a gradual increase after icv injection of rKp-52 (0.1 nmol, approximately 30 times lower dose than iv injection per animal) and remained high for the rest of the sampling period ( Fig. 2A) . On the other hand, icv injection of rKp-10 and hKp-10 at the same dose (0.1 nmol) failed to increase the plasma LH level. The plasma LH level was increased by a higher dose (1 nmol, icv) of rKp-10 and hKp-10, but the increase was lower than that of rKp-52 (0.1 nmol, icv; Fig. 2A ).
Intravenous injection of rKp-52, rKp-10 or hKp-10 also stimulated LH secretion in intact male rats at 10 or 100 nmol/kg (Fig. 2B) . The plasma LH level peaked within 30 min in all groups receiving iv injection of rKp-52, rKp-10 or hKp-10 at 10 or 100 nmol/kg. In the rKp-52 (10 nmol/kg)-treated animals, the plasma LH concentration remained high till 60-min postinjection and then declined gradually to basal levels at the end of the sampling period (Fig. 2B ). On the other hand, rKp-10-and hKp-10-injected animals showed a more rapid decline in plasma LH level after the peak found at around 30 min after injections at both middle (10 nmol/kg) and high (100 nmol/kg) doses. The lowest dose (1 nmol/kg) of rKp-52 or rKp-10 induced only a slight increase in the plasma LH level. [1] and rat [11] kisspeptin. Numbers indicate amino acid residues. Identical amino acid residues are marked with asterisks. The shaded box shows the Kp-10 region that is especially conserved among species.
Effect of icv or iv injection of kisspeptins on AUC of LH release in male rats
The AUC value was significantly higher in icv rKp-52-treated animals at 0.1 nmol (P<0.05, Bonferroni multiple comparison) compared to the controls throughout the sampling period (Fig. 3A) . The rats treated with 0.1 nmol icv treatment of rKp-10 or hKp-10 showed no significant increase throughout the sampling period. In icv rKp-10-treated rats at a 10-times higher dose (1 nmol), the AUC value was significantly higher (P<0.05) than in the controls during the first hour of the sampling period, but not the last 2 h. Animals treated with icv hKp-10 at the higher dose (1 nmol) did not show a significant increase in the plasma LH level throughout the sampling period.
All of the kisspeptins, such as rKp-52, rKp-10 and hKp-10, induced significant increase in AUC values at 10 nmol/kg (P<0.05) compared with the vehicle-treated controls in the first hour of the sampling period (Fig. 3B ). In the second hour of the sampling period, only the animals treated with iv rKp-52 showed a signifi-cant increase in plasma LH level (P<0.05) compared with the controls. In the last hour of the sampling period, the AUC values were not significantly different from the controls in any of the groups at 10 nmol/kg. Intravenous injection of rKp-10 or hKp-10 induced an increase in the plasma LH level at 100 nmol/kg that was similar to that observed at 10 nmol/kg.
Discussion
The present study showed that icv injection of full-length kisspeptin (rKp-52) showed a potent stimulatory effect on LH release for more than 3 h. In the icv experiment, Kp-52 showed more potent LH-releasing activity with a longer duration compared with the icv C-terminal decapeptide (rKp-10 or hKp-10). Both types of Kp-10 induced a smaller increase in LH release at a higher dose (1 nmol) compared with the rKp-52 (0.1 nmol, icv)-injected group. This is inconsistent with an earlier study reporting that hKp-54 and hKp-10 injections into the lateral cerebroventricle show a similar potency to stimulate LH release in male mice [17] . In addition, hKp-10 and hKp-54 have similar affinities or potencies to induce a cellular response in KISS1R-expressing cell lines in vitro [1, 24] . We do not know the reason for the inconsistency between the present results and previous in vivo and in vitro results at present. For in vivo conditions, there might be several possible reasons for the inconsistency. First, Gottsch et al. [17] collected blood samples once 30 min after icv injection and might have missed the plasma LH peak, which was found after the first hour in the fulllength kisspeptin-treated animals in the present study. Second, mice could have same sensitivity to hKp-54 and hKp-10, but rats could respond more to rKp-52 than to rKp-10 or hKp-10. The present results showed that there is a big difference in LH-releasing activity between full-length kisspeptin and C-terminal fragments. A possible explanation for this is degradation. Rat and human Kp-10 are degraded much faster than rKp-52 in the cerebroventricle, so the Kp-10 peptide disappears immediately after injection at a lower dose. The present results raise another possibility that the functional region for kisspeptin bioactivity resides not only in the Cterminal region but also other regions of the rKp-52. To test the latter possibility, in vivo animal models will be needed to examine various kisspeptin fragments for their LH-releasing activity and degradation. Intravenous injection of full-length rat kisspeptin also has a long-lasting effect on LH release. Plasma LH concentrations show an increase for more than 1 h after iv injection of rKp-52 but only for less than 1 h after iv injection of rKp-10 or hKp-10. Matsui et al. [13] also showed that subcutaneous injection of hKp-54 has a long-lasting effect on LH release in male rats. Thompson et al. [15] showed that hKp-10 transiently increases the plasma LH level in male rats. All of these studies demonstrate that the plasma LH level shows a steep increase after injection of full-length kisspeptin or Kp-10. In this context, the longer-lasting effect of full-length kisspeptin could be due to its slower cleavage from the circulation compared with Kp-10. Indeed, Kp-10 has been reported to be completely digested in murine serum within 1 h [25] .
The present study also suggests that the stimulatory effects of icv injection of full-length kisspeptin at 0.1 nmol/animal last longer compared with iv injection of rat or human Kp-10 at about 3 nmol/ animal. A previous study also reported that icv injection of hKp-10 showed a longer stimulatory effect on LH release compared with that of iv injection [15] . Slower degradation of kisspeptin in the cerebroventricle would still be a cause for the longer effect on LH secretion compared with iv administration. Multiple action sites could also be taken in account to explain the difference in LH response to kisspeptins between central and peripheral injections. Since the stimulatory effect of peripheral injection of kisspeptins on LH release is reportedly blocked by GnRH antagonist [13, 17] , one of the action sites of peripherally injected kisspeptins might be GnRH nerve terminals in the median eminence. Indeed, Colledge's group reported that in vitro GnRH release is stimulated by kisspeptin from the MBH [21] . They also suggested the presence of KISS1R protein around the median eminence, where GnRH neuronal terminals are located [21] . On the other hand, centrally injected kisspeptin may also act on GnRH neuronal cell bodies in addition to the nerve terminals. Kisspeptin neuronal fibers are found in close apposition with GnRH cell bodies in the preoptic area (POA), and POA injection of kisspeptin stimulates LH release in female rats [16] . In addition, POA infusion of an antibody for kisspeptin blocks both spontaneous and estrogen-induced LH surges [16, 26] . These results suggest that GnRH neuronal cell bodies in the POA could be another action site of kisspeptins. It is tempting to speculate that the acute stimulatory action of endogenous kisspeptins on LH release might be mediated by GnRH neuronal terminals and that the long-lasting action of full-length kisspeptin on LH release might be mediated via GnRH neuronal cell bodies.
In summary, the present study demonstrated a more potent LHreleasing activity for full-length kisspeptin (rKp-52) compared with C-terminal decapeptide (rKp-10 or hKp-10) when injected centrally or peripherally. The difference in LH-releasing activity may be the results of a difference in degradation of the peptides, but it is still worth determining whether an active domain other than the C-terminal decapeptide is present in full-length kisspeptin. the Japanese Ministry of Education, Culture, Sports, Science and Technology. The RIA was performed at the Nagoya University Radioisotope Center.
